
Presented at #ASCO26: In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: nej.md/3RuNe00 Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW @ASCO

















